SUBSCRIBE
SUBSCRIBE

SystImmune, Inc.

NEWS
Pictured: Bristol Myers Squibb in NJ/iStock, arlut
Business
BMS Inks Potential $8.4B Deal for SystImmune’s ADC for Lung, Breast Cancer
Bristol Myers Squibb has bought the rights to develop and commercialize SystImmune’s potentially first-in-class, bi-specific antibody-drug conjugate for lung and breast cancer as well as other solid tumors.
December 12, 2023
 · 
2 min read
 · 
Tristan Manalac
IN THE PRESS
Press Releases
SystImmune, Inc. to Present Updated BL-B01D1 Data in Breast Cancer at SABCS Congress 2024
December 11, 2024
 · 
4 min read
Press Releases
SystImmune, Inc. Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
November 26, 2024
 · 
4 min read
Press Releases
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M17D1 in Advanced Solid Tumors
November 8, 2024
 · 
3 min read
Press Releases
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
October 14, 2024
 · 
3 min read
Press Releases
SystImmune, Inc. to Present New BL-B01D1 Data in Urothelial, Biliary Tract, and Esophageal Squamous Cell Carcinoma at ESMO Congress 2024
September 9, 2024
 · 
5 min read
Business
SystImmune, Inc. Announces Transition of Chief Medical Officer
May 23, 2024
 · 
2 min read
Business
SystImmune, Inc. Appoints Dr. Jie D’Elia as Chief Executive Officer
April 22, 2024
 · 
2 min read
Business
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
December 11, 2023
 · 
8 min read
BioForest
SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical Trial Results at the 2024 San Antonio Breast Cancer Conference and US Clinical Trial Developments
December 5, 2023
 · 
7 min read
BioForest
SystImmune, Inc. to Present New Oncology Pipeline Data at ESMO Congress 2023
October 20, 2023
 · 
5 min read
Load More
JOBS